# Phase 2 fibrosis trials recruiting: 68 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 68 trials in phase 2 for fibrosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 fibrosis trials: 68 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/fibrosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 68
- Recruiting or not yet: 68
- Read on: November 19, 2026

## Trials

The 25 newest of 68, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933328 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) | Regeneron Pharmaceuticals | Phase 2 | Not yet recruiting | Alcohol-Associated Liver Disease, ALD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933328) |
| November 12, 2026 | NCT07933133 | A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult... | CSPC-NBP Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933133) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 6, 2026 | NCT07921082 | Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II... | Dow University of Health Sciences | Phase 2 | Not yet recruiting | Oral and Maxillofacial Conditions | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921082) |
| November 2, 2026 | NCT07909655 | A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909655) |
| October 9, 2026 | NCT07869147 | Study of ORJ-001 for the Treatment of IPF | Oorja Bio, Inc. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869147) |
| October 7, 2026 | NCT07862634 | A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis | Agomab Spain S.L.U. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862634) |
| August 13, 2026 | NCT07763015 | Study of Resmetirom in Children and Adolescents With MASH | Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763015) |
| July 27, 2026 | NCT07728721 | Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728721) |
| July 7, 2026 | NCT07688070 | Verapamil Effect in Cystic Fibrosis-related Dysglycemia | Rhode Island Hospital | Phase 2 | Not yet recruiting | Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688070) |
| July 1, 2026 | NCT07679893 | Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis | Mannkind Corporation | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679893) |
| June 30, 2026 | NCT07674745 | Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis | University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674745) |
| June 17, 2026 | NCT07652658 | A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. | AstraZeneca | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 359 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652658) |
| June 8, 2026 | NCT07631637 | Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis, MASH | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631637) |
| May 20, 2026 | NCT07600021 | A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis | InnovStone Therapeutics Limited | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07600021) |
| May 13, 2026 | NCT07583589 | Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583589) |
| May 7, 2026 | NCT07572383 | Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Interstitial Lung Disease, Pulmonary Fibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572383) |
| April 30, 2026 | NCT07559175 | A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. | Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | Recruiting | Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559175) |
| April 14, 2026 | NCT07528690 | Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) | VA Office of Research and Development | Phase 2 | Not yet recruiting | Hepatic Encephalopathy, Cirrhosis | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528690) |
| April 8, 2026 | NCT07516951 | A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516951) |
| March 19, 2026 | NCT07481734 | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease | Hudson Biotech | Phase 2 | Recruiting | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481734) |
| March 4, 2026 | NCT07450547 | Phase 2 Study to Assess the Safety and Efficacy of ANG003 | Anagram Therapeutics, Inc. | Phase 2 | Recruiting | Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07450547) |
| March 3, 2026 | NCT07447102 | Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis | Dragonboat Biopharmaceutical Company Limited | Phase 2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447102) |
| January 13, 2026 | NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335601) |
| January 12, 2026 | NCT07333183 | A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | Pulmovant, Inc. | Phase 2 | Recruiting | Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333183) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 2 |
| M.D. Anderson Cancer Center | 2 |
| [Madrigal Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/madrigal-pharmaceuticals-inc) | 2 |
| Avalyn Pharma Inc. | 2 |
| University of Kansas Medical Center | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Pulmovant, Inc. | 1 |
| 4D Molecular Therapeutics | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Aimmune Nestlé Health Science US R&D, LLC | 1 |
| Ruijin Hospital | 1 |
| Centre Hospitalier Universitaire Vaudois | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| InnovStone Therapeutics Limited | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| The Hospital for Sick Children | 1 |
| Rhode Island Hospital | 1 |
| King Edward Medical University | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| Shanghai Synvida Biotechnology Co.,Ltd. | 1 |
| BiomX Ltd | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Agomab Spain S.L.U. | 1 |
| [Cumberland Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/cumberland-pharmaceuticals) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 44 |
| United Kingdom | 11 |
| Canada | 9 |
| Spain | 8 |
| Germany | 8 |
| Poland | 7 |
| China | 7 |
| Australia | 6 |
| France | 6 |
| Italy | 5 |
| South Korea | 5 |
| Bulgaria | 4 |
| Argentina | 3 |
| New Zealand | 3 |
| Denmark | 3 |
| Greece | 3 |
| Israel | 3 |
| Japan | 3 |
| Taiwan | 3 |
| Belgium | 3 |
| Hungary | 2 |
| Czechia | 2 |
| Netherlands | 2 |
| Chile | 2 |
| Mexico | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bathtub and sink repair companies in the United States](https://specstream.ai/data/businesses/bathtub-and-sink-repair-companies/united-states)
- [Credit and debt counseling services in the United States](https://specstream.ai/data/businesses/credit-and-debt-counseling-services/united-states)
- [Fondue restaurants in the United States](https://specstream.ai/data/businesses/fondue-restaurants/united-states)
- [IT consultants in the United States](https://specstream.ai/data/businesses/it-consultants/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
